Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 226

1.

Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries.

Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, Dillner J, Meijer CJ.

Vaccine. 2008 Aug 19;26 Suppl 10:K29-41. doi: 10.1016/j.vaccine.2008.06.019. Review.

PMID:
18847555
2.

Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.

Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, Koliopoulos G, Naucler P, Sankaranarayanan R, Peto J.

Vaccine. 2012 Nov 20;30 Suppl 5:F88-99. doi: 10.1016/j.vaccine.2012.06.095. Review. Erratum in: Vaccine. 2013 Dec 16;31(52):6266.

PMID:
23199969
3.

The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.

C Kitchener H, Canfell K, Gilham C, Sargent A, Roberts C, Desai M, Peto J.

Health Technol Assess. 2014 Apr;18(23):1-196. doi: 10.3310/hta18230.

5.

Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions.

Arbyn M, Roelens J, Simoens C, Buntinx F, Paraskevaidis E, Martin-Hirsch PP, Prendiville WJ.

Cochrane Database Syst Rev. 2013 Mar 28;(3):CD008054. doi: 10.1002/14651858.CD008054.pub2. Review.

PMID:
23543559
6.

Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses.

Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J.

Vaccine. 2006 Aug 31;24 Suppl 3:S3/78-89. Review.

PMID:
16950021
7.

Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.

Castle PE, Stoler MH, Wright TC Jr, Sharma A, Wright TL, Behrens CM.

Lancet Oncol. 2011 Sep;12(9):880-90. doi: 10.1016/S1470-2045(11)70188-7.

PMID:
21865084
8.

[Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].

Ronco G, Biggeri A, Confortini M, Naldoni C, Segnan N, Sideri M, Zappa M, Zorzi M, Calvia M, Accetta G, Giordano L, Cogo C, Carozzi F, Gillio Tos A, Arbyn M, Mejier CJ, Snijders PJ, Cuzick J, Giorgi Rossi P.

Epidemiol Prev. 2012 May-Aug;36(3-4 Suppl 1):e1-72. Italian.

9.

Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening.

Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, Rådberg T, Strander B, Forslund O, Hansson BG, Hagmar B, Johansson B, Rylander E, Dillner J.

J Natl Cancer Inst. 2009 Jan 21;101(2):88-99. doi: 10.1093/jnci/djn444.

10.

[Use of high-risk human papillomavirus DNA testing to deal with atypical squamous cells undetermined significance and low squamous intraepithelial lesion].

Guo YL, You K, Geng L, Zhang XW, Shen XY, Yao YJ, Fan XH.

Beijing Da Xue Xue Bao. 2006 Oct 18;38(5):480-2. Chinese.

11.

Screening for cervical cancer: new alternatives and research.

Lörincz AT.

Salud Publica Mex. 2003;45 Suppl 3:S376-87. Review.

PMID:
14746031
12.

Prediction of cervical intraepithelial neoplasia grade 2+ (CIN2+) using HPV DNA testing after a diagnosis of atypical squamous cell of undetermined significance (ASC-US) in Catalonia, Spain.

Ibáñez R, Moreno-Crespi J, Sardà M, Autonell J, Fibla M, Gutiérrez C, Lloveras B, Alejo M, Català I, Alameda F, Casas M, Bosch FX, de Sanjosé S.

BMC Infect Dis. 2012 Jan 26;12:25. doi: 10.1186/1471-2334-12-25.

13.

Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.

Kulasingam SL, Hughes JP, Kiviat NB, Mao C, Weiss NS, Kuypers JM, Koutsky LA.

JAMA. 2002 Oct 9;288(14):1749-57.

PMID:
12365959
14.

Cytology and human papillomavirus testing 6 to 12 months after ASCUS or LSIL cytology in organized screening to predict high-grade cervical neoplasia between screening rounds.

Tropé A, Sjøborg KD, Nygård M, Røysland K, Campbell S, Alfsen GC, Jonassen CM.

J Clin Microbiol. 2012 Jun;50(6):1927-35. doi: 10.1128/JCM.00265-12.

15.

HPV testing with cytology triage for cervical cancer screening in routine practice.

Louvanto K, Chevarie-Davis M, Ramanakumar AV, Franco EL, Ferenczy A.

Am J Obstet Gynecol. 2014 May;210(5):474.e1-7. doi: 10.1016/j.ajog.2013.12.033.

PMID:
24373948
16.

Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.

Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, Tarkkanen J, Laurila P, Anttila A.

J Natl Cancer Inst. 2009 Dec 2;101(23):1612-23. doi: 10.1093/jnci/djp367.

17.

Performance of HPV DNA testing with hybrid capture 2 in triaging women with minor cervical cytologic abnormalities (ASC-US/LSIL) in Northern Thailand.

Khunamornpong S, Settakorn J, Sukpan K, Srisomboon J, Suprasert P, Siriaunkgul S.

Asian Pac J Cancer Prev. 2014;15(24):10961-6.

18.

Chapter 10: New dimensions in cervical cancer screening.

Cuzick J, Mayrand MH, Ronco G, Snijders P, Wardle J.

Vaccine. 2006 Aug 31;24 Suppl 3:S3/90-7. Review.

PMID:
16950022
19.

Triage of women with minor abnormal cervical cytology: meta-analysis of the accuracy of an assay targeting messenger ribonucleic acid of 5 high-risk human papillomavirus types.

Verdoodt F, Szarewski A, Halfon P, Cuschieri K, Arbyn M.

Cancer Cytopathol. 2013 Dec;121(12):675-87. doi: 10.1002/cncy.21325. Review.

20.

Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia.

Arbyn M, Buntinx F, Van Ranst M, Paraskevaidis E, Martin-Hirsch P, Dillner J.

J Natl Cancer Inst. 2004 Feb 18;96(4):280-93.

Items per page

Supplemental Content

Support Center